Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Rises By 52.5%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 10,830,747 shares, a growth of 52.5% from the December 15th total of 7,101,931 shares. Based on an average daily volume of 1,852,202 shares, the short-interest ratio is currently 5.8 days. Approximately 15.7% of the shares of the stock are short sold. Approximately 15.7% of the shares of the stock are short sold. Based on an average daily volume of 1,852,202 shares, the short-interest ratio is currently 5.8 days.

Lexeo Therapeutics Stock Down 1.5%

NASDAQ LXEO traded down $0.11 during trading on Friday, reaching $7.39. 1,026,289 shares of the stock traded hands, compared to its average volume of 1,662,542. Lexeo Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $10.99. The firm has a market cap of $539.40 million, a price-to-earnings ratio of -2.74 and a beta of 1.75. The stock’s 50-day moving average price is $9.41 and its 200 day moving average price is $7.15.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15. Analysts anticipate that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LXEO. Raymond James Financial initiated coverage on shares of Lexeo Therapeutics in a research report on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price objective for the company. HC Wainwright dropped their target price on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Chardan Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald assumed coverage on Lexeo Therapeutics in a report on Monday, December 1st. They set an “overweight” rating and a $19.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lexeo Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $19.00.

Institutional Investors Weigh In On Lexeo Therapeutics

Large investors have recently modified their holdings of the business. CWM LLC lifted its holdings in shares of Lexeo Therapeutics by 150.3% during the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after purchasing an additional 6,216 shares in the last quarter. Ethic Inc. acquired a new stake in Lexeo Therapeutics during the 2nd quarter worth approximately $44,000. Cerity Partners LLC bought a new position in Lexeo Therapeutics in the second quarter valued at approximately $50,000. Intech Investment Management LLC boosted its holdings in shares of Lexeo Therapeutics by 20.7% in the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after buying an additional 2,342 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Lexeo Therapeutics in the second quarter valued at approximately $60,000. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.